Thus, we reasoned that metastases from cancer patients would have equal or elevated Ki-67 expression compared to corresponding primary lesions from the same patient if Ki-67 expression was indeed modulating a CSC niche, resulting in therapeutic resistance and an increased metastatic potential. Here, MKI67 is linked to cancer.